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ABSTRACT 
Whether transitioning from paper to electronic records or attempting to leverage data from existing systems for 
outcome studies, oncology practices face many challenges in defining and executing an informatics strategy. With the 
increasing  costs  of  oncology  treatments  and  expected  changes  in  reimbursement  rules,  including  requirements  for 
evidence that supports physician decisions, it will become essential to collect data on treatment decisions and treatment 
efficacy to run a successful program. This study evaluates the current state of informatics systems available for use in 
oncology programs and focuses on developing an informatics strategy to meet the challenges introduced by expected 
changes  in  reimbursement  rules  and  in  medical  and  information  technologies.  © 2008  Biomedical  Imaging  and 
Intervention Journal. All rights reserved. 
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INTRODUCTION 
Whether  transitioning  from  paper  to  electronic 
records  or  attempting  to  leverage  data  from  existing 
systems  for  outcome  studies,  oncology  practices  face 
many  challenges  in  defining  and  executing  an 
informatics  strategy.  With  the  increasing  cost  of 
oncology  treatments  and  expected  changes  in 
reimbursement  rules,  including  requirements  for 
evidence  that  supports  physician  decisions,  it  will 
become essential to collect data on treatment decisions 
and treatment efficacy to run a successful program. 
The  ability  to  measure  efficacy  of  care  and  to 
identify  actionable  areas  for  improvement  has  proven 
evasive  in  the  specialty  healthcare  software  market. 
Oncology electronic medical record systems (EMRs) are 
largely workflow centric, focusing mainly on a series of 
tasks, but not on facilitating real time decision making 
and comprehensive outcomes collection. 
The treatment of cancer requires long term patient 
management,  which  often  spans  decades.  Each  patient 
case  can  have  a  significant  amount  of  information 
ranging  from  test  results  to  medical  administration 
records,  clinical  evaluation notes, as  well  as  insurance 
and billing records. As a result, there is a wealth of data 
collected  over  time  on  the  diagnosis,  treatment  and 
outcomes, but most often this data resides only on paper. 
Transitioning from paper to an electronic medical record 
system  or  even  supplementing  paper  records  with  an 
EMR involves significant time and manpower for data 
entry, training and maintenance.  
Oncology  information  systems  must  support  the 
collection of relevant data for today’s medical practices, 
while  also  allowing  for  the  integration  of  future 
developments in the medical field. Evolving technology 
will  result  in  more  personalised  medicine  with  rapid 
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feedback mechanisms. It is important for an electronic 
oncology  system  to  have  the  ability  to  interface  with 
these  technologies  in  order  to  diagnose  response  to 
treatment and incorporate new knowledge into standards 
of  care  when  appropriate.  Interoperability  with  new 
clinical tools and systems will be critical in maintaining 
accurate and complete patient records. 
Economics 
Performance  will  be  the  key  economic  factor  for 
oncologists and oncology practices. As the medical field 
becomes increasingly focused on pay for performance, it 
is  inevitable  that  hospitals,  insurance  companies  and 
other  organisations  will  increase  their  quality  of  care 
requirements. Business administrators must consider the 
following: 
●  Fee For Service  (FFS)  reimbursement 
programs  are  being  replaced  by  value based 
systems such as Pay For Performance (P4P) in 
the  U.S.  and  by  other  performance based 
systems globally [1, 2]. 
●  P4P will be based on quality indicators that are 
more  meaningful  and  derived  from  specific 
diagnostic tests. 
●  Measuring  response  to  treatment  and  toxicity 
will  be  critical  to  ensure  an  accurate 
performance metric for reimbursement [1, 4]. 
●  Outcomes  and  performance  indicators  will  be 
based on current data and compared across the 
industry. 
●  Potential  benefits  will  appear  from  sharing 
highly  effective  treatment  plans  with  other 
physicians and practices. 
●  Performance based  programs  will  influence 
standards of care that the industry can use to set 
prices and reimbursement rates. 
As performance becomes the key economic factor 
for the physician, it is critical for oncology systems to 
generate  reports  on  cost  performance  and  to  facilitate 
outcome studies that show quality performance based on 
treatment  efficacy  and  toxicities.  Practices  will  be 
‘rewarded’  for  demonstrating  quality  and  efficiency  in 
care  delivery  [1 4].  ‘Normative’  economics  will  steer 
decision making  to  consider  the  cost/value  ratio  of  a 
procedure  in  relation  to  potential  outcome.  Insurance 
companies  will  require  detailed  evidence  of  specific 
conditions  before  approving  procedures  and  drugs. 
Segmenting a provider’s patients into logical groupings 
based  on  condition/progress  will  be  essential  when 
approximating  financials,  measuring  outcomes  and 
comparing performance. Biotechnology, pharmaceutical 
and medical device vendors will be forced to price their 
products based on evidentiary positive results. 
This  study  will  evaluate  the  current  state  of 
informatics  systems  available  for  use  in  oncology 
programs. It is expected that the abilities of the currently 
available  systems  will  not  be  fully  aligned  with  the 
primary  needs  of  the  oncology  field.  The  functional 
capabilities  and  problems  with  oncology  informatics 
today will be compared to the needs of the stakeholders 
and,  if  applicable,  suggestions  to  improve  the 
development  of  electronic  oncology  systems  will  be 
made. In particular, suggestions will focus on developing 
an informatics strategy to meet the challenges introduced 
by  expected  changes  in  reimbursement  rules  and  in 
medical and information technologies. 
A TOP-DOWN APPROACH 
Oncology Informatics Stakeholders 
A  review  of  oncology  informatics  must  start  by 
looking  at  the  information  needs  of  the  various 
stakeholders  who  serve  to  gain  from  a  more  efficient 
method of tracking patient information. Care providers, 
administrators,  insurance  companies,  and  patients  are 
just  a  few  examples  of  these  stakeholders.  Data 
requirements  range  from  individual  patient  records  to 
aggregate  sets  of  data  for  analysis  and  reporting.  As 
shown  in  Figure  1,  the  data  and  functionality  most 
relevant  to  the  majority  of  stakeholders  involves  the 
synthesis and aggregation of information, not those that 
involve highly detailed individual patient data. 
Care providers have an interest in all clinical data 
associated with the patient. Clinicians and administrators 
need a way to track a patient’s overall status, including 
treatment  plan,  response  to  treatment,  toxicities 
associated  with  treatment,  and  information  specific  to 
clinical  trials.  Physicians  rely  on  a  patient’s  data  for 
diagnosis and care decisions. Administrators look at data 
aggregates to assess quality of care and compliance to 
standards. 
As  shown  in  Figure  2,  external  entities  including 
insurance  companies,  drug  and  equipment  vendors, 
tumour  registries  and  government  agencies  provide 
influence  related  to  costs,  reimbursements,  treatment 
efficacy,  and  diagnostic  efficacy,  all  of  which  may  be 
used by the oncology practice as the basis for decision 
making. Clinical and business knowledge can be shared 
with  external  entities  to  leverage  contractual 
arrangements,  benefit  public  domain  medical 
information,  and  improve  quality  of  care.  These 
stakeholders  can  then  use  this  knowledge  to  fine tune 
costs, rates, and their contractual commitments. 
Research and registry department stakeholders are in 
need  of  tools  to  retrieve,  synthesise,  and  aggregate 
information from patient charts for registry reporting and 
outcome studies. When done manually, this is a labour 
intensive  and  lengthy  process  that  can  take  several 
months. Clinical systems available today do not provide 
tools  to  meet  business  requirements  for  registry  or 
outcome studies.  
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Figure 1  Relevance of Functionality to Stakeholder. 
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INFORMATICS ADDRESSING THE NEEDS OF TODAY’S 
ONCOLOGY PRACTICES 
In  today’s  healthcare  information  technology 
environment, there are a number of systems that focus on 
specific tasks. Some systems are suitable for any type of 
ambulatory  setting  and  thus  can  be  used  in  oncology 
practices.  However,  only  a  small  number  of  systems 
have been developed specifically for the oncology space. 
An example of the latter would be the systems used with 
oncology  treatment  equipment  that  rely  on  integrated 
software to control and support radiotherapy and infusion 
administration.  
Informatics  technologies  supporting  the  oncology 
business practice and patient medical records fall into the 
following categories:  
Practice Management Systems 
Practice  Management  systems,  providing  patient 
registration,  scheduling  and  billing  functionality,  are  a 
logical  first  step  in  producing  an  electronic  medical 
record. The foundation of the patient record is built by 
collecting  patient  demographics  and  insurance 
information, and tracking patient visits and services for 
billing  purposes.  Billing  functionality  supports  the 
labour intensive tasks and expensive medical equipment 
usage,  and  ensures  the  accuracy  required  to  generate 
revenue for the business. There are several systems that 
have  been  designed  for  use  in  any  type  of  medical 
practice  and  can,  therefore,  be  applied  to  oncology 
practices. These Practice Management systems continue 
to mature. 
Electronic Medical Record Systems 
Electronic  Medical  Record  (EMR)  systems  are 
typically  seen  as  the  next  step  in  moving  toward 
electronic  patient  records.  EMR  systems  facilitate 
workflow in the office, provide forms and functionality 
for clinical documentation and visit management, track 
treatment administration, and support order entry. EMRs 
usually  include  automated  dosage  validation,  and  drug 
interaction  and  allergy  alerts  when  placing  orders. 
Compared  to  practice  management  systems,  there  are 
fewer  oncology  EMR  systems  from  which  to  choose. 
Some EMR vendors are in the early stages of integrating 
records for medical oncology and radiation oncology, but 
for the most part, EMR systems are designed to meet the 
needs of one modality or the other. Built for ambulatory 
 
Figure 2  A Top Down Approach. 
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settings,  there  is  little  or  no  tracking  of  a  patient’s 
inpatient care. 
 Clinical Decision Support Systems 
The importance of clinical decision support systems 
that guide patient care and ensure patient safety is well 
recognised, although such systems are still in the very 
early stage of implementation for the oncology practice. 
At  its  best,  the  clinical  decision  support  system  will 
focus  on  providing  diagnostic  test  results  to  inform 
physicians  during  decision making  and  will  document 
the evidence used to support decisions. Tools will allow 
for the analysis of discrete evidence to provide better, 
more  cost effective  guidelines  for  diagnostic  testing. 
Rules  engines  will  be  responsible  for  presenting 
treatment  guidelines  to  physicians  at  the  point  of  care 
based  on  disease  and  stage  diagnosis,  relevant  patient 
characteristics,  and  treatment  history.  Alerts  will  warn 
the  physician  when  a  patient  co morbidity  puts  the 
patient  at  greater  risk  for  toxicities  associated  with  an 
intervention.  Knowledge  obtained  from  studies  of 
treatment  efficacy  and  toxicities  will  be  used  to 
recommend and improve treatments. Industry standards 
from  organisations  such  as  National  Comprehensive 
Cancer Network (NCCN), American Joint Committee on 
Cancer  (AJCC),  College  of  American  Pathologists 
(CAP),  and  National  Cancer  Institute  (NCI)  will  be 
incorporated  for  decision  support.  Physicians  will  be 
guided to follow site defined standards of care. Cost and 
reimbursement of treatments and testing will be tracked 
against  studies  of  treatment  and  testing  efficacy, 
allowing for improvements to the financial health of the 
organisation  and  for  use  in  facilitating  contract 
negotiations. 
Clinical Standards of Care Authoring 
Establishing  intervention  standards  of  care  for  an 
oncology  organisation  is  facilitated  with  tools  for 
authoring,  making  revisions,  providing  references  and 
citations,  and  managing  the  approval  process.  The 
authoring tool allows interventions and treatment plans 
to be tied to specific cancer profiles and to be prioritised 
based on outcome and economic factors. This tool also 
facilitates  the  creation  and  maintenance  of  order  sets 
associated with interventions. Working together with a 
decision  support  system,  internal  treatment  guidelines 
can be recommended when appropriate for the patient, 
disease, and stage. Analytical tools that provide costs and 
expected reimbursements for treatments can assist with 
the  authoring.  Reports  on  compliance,  based  on  data 
from  decision  support,  can  help  to  identify  issues  and 
improve standards. Although authoring systems do exist, 
systems  designed  specifically  for  authoring  oncology 
treatment plans based on cancer diagnosis and stage are 
not found in today’s market. 
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Figure 3  Oncology Informatics. 
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Outcome Studies 
By  tracking  the  response  of  the  disease  and  the 
patient to treatment, outcome studies are made possible. 
Collecting data specific to the diagnosis of disease and 
stage, monitoring the status of disease with a minimal set 
of relevant questions, recording the use of interventions, 
the  response  of  the  disease  to  treatment,  and  the 
toxicities  experienced  by  the  patient,  as  well  as 
documenting  evidence  that  supports  the  diagnosis  of 
disease,  stage  and  response  creates  a  rich  knowledge 
base  that  fosters  an  environment  of  continual 
improvement  based  on  acquired  evidence.  Knowledge 
will be the key competitive differentiator for physicians. 
Guideline  collaboratives  will  evolve,  allowing  smaller 
practices to remain competitive. Software will facilitate 
the  ability  to  tie  guidelines  and  protocols  to  specific 
condition  profiles  and  to  prioritise  their  use  based  on 
outcome  and  economic  factors.  Practices  will  be 
positioned  to  respond  to  payer  priorities  for  highly 
effective diagnostics and treatments. 
Clinical Trial Management 
According to a statement on the caBIG website:  
“At present, there is no standardized, uniform 
system  for  clinical  trial  management,  and  no 
central  registry  of  all  cancer-related  clinical 
trials. Moreover, only a small number of cancer 
patients actually participate in clinical trials of 
experimental  therapies.  ‘Legacy,’  or  paper-
based,  information  systems  for  clinical  trials 
are  slow  and  inefficient  for  the  collection, 
analysis  and  sharing  of  data,  resulting  in 
unnecessary work delays, duplication of effort, 
human  errors  in  data  entry,  and  missed 
opportunities  for  data  mining  and  secondary 
use of the data.” [5]  
As more software is developed in this area, it will be 
important to look for interoperability, discrete eligibility 
requirements, and financial management functionality.  
Ancillary Systems 
Oncology  is  supported  by  specialised  and  mature 
ancillary  systems  that  are  used  throughout  healthcare, 
including: 
●  Radiographic,  pathologic,  and  lab  diagnostics 
systems. 
●  Drug  dispensing  and  inventory  management 
systems. 
●  Dictation systems that provide transcribed notes 
to EMR systems. 
Expectations 
As ambulatory services grow, the healthcare field is 
beginning  to  see  growth  in  software  development  for 
ambulatory  settings.  Gartner,  the  global  leader  in 
providing  accurate  and  current  research  for  the 
information technology industry, predicts that there will 
be  mainstream  adoption  of  ambulatory  EMR  systems 
within  two  to  five  years  [6].  The  number  of  practice 
management systems and EMR systems aimed at either 
radiation  oncology  or  medical  oncology  has  grown  in 
recent years. As these begin to mature, we will start to 
see IT vendors’ focus shifting towards the integration of 
medical, radiation, and surgical records, interoperability 
of EMR and diagnostic systems, as well as development 
of clinical decision support systems and data repositories 
that support research and outcome studies. Strategies will 
be  developed  to  address  the  implementation  and 
workflow  issues  presented  by  stand alone  practices, 
integrated  oncology  practice  networks,  and  large 
academic hospital based centres. 
PROBLEMS WITH EXISTING ONCOLOGY SYSTEMS 
Interoperability 
System interoperability is required to ensure critical 
patient  data  is  shared  across  all  healthcare  systems. 
Electronic  medical  systems  are  often  designed  for  one 
part of the oncology care team. With limited sharing of 
information, there can be unnecessary repetition of costly 
and potentially painful diagnostic procedures. Areas in 
need of enhanced interoperability include: 
●  Integrated views across care settings including 
medical,  radiation,  and  surgical  oncology  in 
both inpatient and ambulatory settings   it will 
be  imperative  for  software  to  facilitate  a 
collaborative care approach. 
●  Clinical,  pathologic,  and  radiographic 
diagnostic results visibility in oncology systems 
as  needed  and  ability  to  add  new  diagnostic 
technologies as they emerge. 
●  Integration  of  clinical  and  financial  business 
systems. 
●  Patient identification technologies. 
●  System  upload/download  capability  to/from 
CDs or cards embedded with computer chips. 
●  Provision of patient identity and order data to 
infusion  pumps,  pharmacy  dispensers,  and 
radiation  therapy  planning  systems  for 
validation, and in turn, treatment data sent back 
for treatment administration records. 
●  Information  exchange  among  practices  within 
an  organisation  and  with  external  healthcare 
organisations  including  tumour  registries  and 
insurance providers.  
●  Standards  for  clinical  terminology  and 
ontology based  semantic  interoperability 
allowing information exchange.  
●  Caregiver  access  to  patient  history,  progress, 
current status, medical necessity, and continuity 
of care data in near real time.  
●  Physician remote access to patient records. 
●  Patient portals for education, financial account 
management,  scheduling,  and  other 
communication with providers. 
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Usability Challenges 
One  of  the  greatest  challenges  facing  IT  vendors 
today  is  integrating  systems  into  the  physician’s  busy 
workflow  without  requiring  additional  time  from  the 
physician. Many hardware solutions including handhelds 
(PDAs),  portables  (tablets/slates),  and  desktops  in  the 
exam  room  are  readily  available.  However,  issues 
regarding patient privacy, time for login, patient search, 
data  entry,  and  the  impact  on  the  physician–patient 
interaction are difficult ones that need to be addressed 
practice by practice,  if  not  physician by physician. 
Changing the culture from paper to electronic notation 
will  require  physician  ‘champions’  to  overcome  the 
barriers. In the end, hardware requirements and staffing 
for  maintenance  of  hardware  and  software  are  often 
beyond  what  a  stand alone  oncology  practice  can 
reasonably manage. 
Data Limitations 
To be effective, data collection and storage must be 
carefully designed. Some problems that oncology system 
users currently face are: 
●  Discrete  data  specific  to  oncology  isn’t 
captured in a way that can be used for reporting, 
trending, or outcome studies. 
●  Physician  decision making  process  is 
documented as textual notes. 
●  Systems aren't adaptable for new technologies 
and  knowledge  content  (e.g.  treatment 
guideline updates).  
●  High percentage of data presented to physician 
is not relevant to oncology treatment . 
●  There  is  no  comprehensive  summary  of  the 
status of disease and patient toxicities. 
●  Registry staff must manually synthesise data in 
charts for tumour registry. 
●  Response to treatment isn’t captured.  
●  Standards  of  care  aren’t  promoted  with 
recommended treatment options.  
●  A treatment feedback loop is not supported – 
for  example:  diagnosis/prognosis,  presentation 
of treatment standards for selection, treatment 
administration,  monitoring/adjustment, 
recording of response, follow up visit, reporting 
/ feedback to improve standards of care. 
●  Summary of care doesn’t clearly represent an 
overview  of  oncology specific  events  or 
timeline with inflection points.  
●  Tracking of treatment efficacy versus costs and 
reimbursement is poorly facilitated.  
●  High  cost  of  data  entry  for  detailed 
research/registry data.  
Keeping Pace with New Technologies  
Electronic  oncology  systems  must  remain  flexible 
and  adaptable  to  allow  for  new  technology  and 
regulation changes. Upcoming changes are expected to 
include: 
Diagnostic Techniques 
Systems must be flexible and able to adapt to the 
growing use of molecular imaging and data such as DNA 
sequencing, levels of genetic expression, biomarkers, and 
protein structure for diagnosis and treatment [7, 8]. The 
ability to look at molecular data together with clinical, 
pathologic and radiographic data will provide a wealth of 
research material and evidence supporting diagnosis and 
treatment decisions. 
Molecular  imaging,  proteomics  and  the  use  of 
biomarkers, and the study of temperature, gravitational 
properties and density changes in tumours are likely to 
make important contributions to diagnostic data. These 
technologies will continue to evolve and will be used to 
identify  and  monitor  response  to  treatment  more 
effectively.  
Treatment Technology 
Support  for  the  administration  of  collaborative 
treatment  plans,  including  chemotherapy, 
immunotherapy,  radiation  therapy,  and  surgery  is 
currently still very much a need in cancer care. Stem cell 
transplants,  cryotherapy,  tomotherapy,  proton  therapy, 
photodynamic  therapy,  and  signal  transduction  therapy 
are  examples  of  interventions  that  are  not  captured 
electronically in existing systems. As new techniques are 
developed  or  become  more  commonly  used,  these  too 
must  be  incorporated  into  systems  to  allow  for  a 
comprehensive look at patient treatment history and care. 
Support  for  site  configurable  treatment  protocols  and 
rules for each type of intervention will also be needed. 
For  order  set  construction,  the  use  of  drugs,  herbs, 
massage, acupuncture, music therapy, and diet to manage 
side effects must be supported. 
Computer Technology and Human Computer 
Interaction (HCI) 
Current initiatives in hardware, communication, and 
application software development will help to make the 
transition to the use of electronic systems a more natural 
fit with physician thought flow and practice workflows. 
Wireless enabled user interfaces, portable devices, and 
touchpad  screens  can  help  with  usability.  Virtualised 
hardware,  operating  systems,  storage,  and  centrally 
hosted software  delivered  as  a  service  (SAAS)  can  be 
used  to  drive  implementation  and  maintenance  costs 
down. Natural Language Processing (NLP) will be used 
to  streamline  data  input  by  saving  physician  dictation 
directly  to  disk.  Work  is  being  done  to  structure  data 
contained in pathology and radiology reports, which will 
provide a comprehensive diagnosis that can be viewed at 
a  very  granular  level  for  analysis  and  studies.  Service 
Oriented  Architectures  (SOA)  and  modularised 
application  components  that  are  interchangeable  and 
reusable  across  the  health  enterprise  will  improve 
information exchange and will facilitate a build as you 
go, prioritised approach to system procurement. Gartner 
predicts that mainstream adoption of Natural Language 
Processing will occur in 2 to 5 years and that adoption of 
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SOA for application integration in healthcare will occur 
in 5 to 10 years, whereas semantic interoperability will 
likely take more than 10 years to become widely adopted 
[9, 10]. 
Global Considerations 
Software products and information resources must 
be designed to meet requirements for customers in any 
country  or  region.  Oncology  centres  that  expand  to 
include practices in multiple countries will need to have 
the ability to configure settings that are appropriate for 
each  practice.  For  example,  configuration  will  be 
required  to  define  units  of  measure;  currency  formats; 
date and time formats; data element types and lengths; 
language  options  for  displays  and  keyboard;  language 
options  for  speech  recognition  and  handwriting 
recognition if these features are supported by the system; 
content  (e.g.  diagnostic  and  billing  codes,  disease  and 
stage  classifications  that  are  suitable  for  the  local 
population);  rules  such  as.  reimbursement  rules  and 
tumour  registry  rules;  local  laws  and  regulations  (e.g. 
some countries require that servers holding patient data 
must be physically located in the country of the treating 
facility);  availability  of  treatments  and  diagnostics 
technologies;  and  implementation  strategies  (e.g.  the 
impact of a change to regional settings at the operating 
system level on other applications).  
In  developing  countries,  lack  of  infrastructure, 
communication services, and access to research findings 
available on the Internet can impede progress and affect 
quality of care [11]. Internet access alone can provide 
many resources to help oncologists throughout the world. 
For  example,  clinical  practice  guidelines  from  the 
National Comprehensive Cancer Network, Inc (NCCN) 
are currently available in English, Spanish, Chinese, and 
Japanese  [12,  13].  Guides  for  developing  countries  on 
medical  records,  electronic  health  records,  and 
improving data quality are provided on a website created 
for the World Health Organization Regional Office for 
the Western Pacific [14]. Quality initiatives are promoted 
on websites such as those described on the website of the 
Taipei Branch of Bureau of National Health Insurance 
[15].  Information  about  the  Quality  and  Outcomes 
Framework  (QOF)  in  England  and  the  Quality 
Management and Analysis System that supports QOF are 
available on a site that provides online help and training 
information  [16].  The  PubMed  Databases  and  search 
engines available on the website of the National Center 
for Biotechnology Information (NCBI) provide a wealth 
of  research  findings.  An  online  search  returns  2328 
citations  when  searching  for  “oncology  in  Asia”  (in 
quotes).  Adding  “and  breast”  (without  quotes)  will 
narrow down the search to 289 results [17]. 
IN SEARCH OF THE IDEAL ONCOLOGY INFORMATION 
SYSTEM 
In a typical medical record (EMR or paper record) 
information  about  the  patient’s  cancer  is  obtained  by 
extracting  data  from  office  notes,  lab  results,  X ray 
reports, and other tests. Even though the clinician has all 
of the above information, he or she is still required to 
synthesise  the  data.  Frequently,  a  summary  of  the 
synthesis is entered as free form text in the office note. 
While the information contained in the note is critical, 
the note itself is often long and complicated.  
Additionally, data from administrative, financial and 
billing systems are not connected with the clinical data in 
any meaningful way. In the newly developing systems of 
insurance,  oncology  practices  will  only  be  reimbursed 
for a drug (often a very expensive drug) if it is approved 
for a particular cancer, a particular stage of that cancer, 
and  sometimes,  even  a  subset  of  the  cancer  that 
expresses  a  certain  laboratory tested  phenotype  or 
genotype.  There  is  currently  no  easy  way  for 
administrative  and  billing  personnel  to  verify  this. 
Furthermore,  the  shift  to  pay for performance 
reimbursement will require an institution to have virtual 
real time access to intervention and response data for the 
various  diseases.  Capitated  insurance  contracts  will 
require  knowing  how  much  is  spent  in  pharmacologic 
therapy, radiation therapy, or surgery to treat a particular 
stage of disease.  
An effective electronic oncology system will be able 
to address these issues by: 1) promoting standards of care; 
2)  supporting  and  capturing  the  physician’s  decision 
making  process  when  diagnosing  disease,  stage  and 
status of disease, when deciding how to treat the disease, 
and  when  determining  response  to  treatment;  3) 
establishing  relationships  of  treatment  to  disease  stage 
and  status  diagnosis,  outcomes,  costs,  and  revenue;  4) 
capturing  outcomes  and  performance  metrics;  and  5) 
associating diagnostic results as evidence that supports 
the diagnosis of disease, stage, and outcomes.  
The development of healthcare systems designed for 
decision support and outcome studies generally follows 
the development of EMR systems. For oncology needs 
however,  it  is  worth  considering  a  different  approach. 
Once  a  Practice  Management  System  has  been 
implemented,  thought  should  be  given  to  planning  for 
clinical decision support and outcome studies as the next 
strategic step. With access to a summary of the patient’s 
full oncology treatment history and records of response 
to treatment, the oncologist will have the support needed 
to  make  individualised  treatment  decisions.  With  the 
support of standards of care that are based on the disease, 
stage, patient and disease characteristics, and evidence of 
successful interventions, the oncologist can be guided to 
treat  effectively  and  consistently  in  all  situations.  The 
innate value of a decision support system will be derived 
from  facilitating,  aiding  and  capturing  the  physician’s 
decision making  process  through  the  continuum  of  the 
patient’s care. Providing the physician with guidance and 
a concise view into the realm of relevant patient disease 
information  will  result  in  clinical  efficiency,  improved 
patient safety, and measurable outcomes.  
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CONCLUSION 
The  development  of  an  informatics  strategy  for 
oncology must start by looking at systems in terms of 
meeting  business  needs  and  goals.  Table  1  illustrates 
some key elements to include in such a strategy.  
The  first  step  is  to  focus  on  business  goals  that 
guarantee: 
●  Patient  safety  is  ensured  with  a  concise 
summary  of  the  history  of  care  and  with 
validation and alerts for dosages, drug to drug 
interactions, and allergy or co morbidity risks. 
●  Metrics  are  collected  and  are  able  to 
demonstrate  treatment  performance  and 
outcomes [18]. 
●  Treatment decisions are guided by standards of 
care that are set according to collected data and 
evidence of treatment efficacy and toxicities. 
●  Diagnostic orders are based on efficacy of the 
test,  technique,  or  procedure  and  diagnosis 
decisions are supported with evidence. 
●  Physicians  and  Administrators  are  enabled  to 
make decisions that are informed by costs and 
revenue  for  treatment  and  diagnostic 
procedures.  
The next step in the strategic process is to define 
requirements  for  systems  that  will  help  to  meet  these 
business goals and that will provide for flexibility, such 
that: 
●  Regulatory  changes  and  new  technologies  in 
diagnostics and treatments can be incorporated 
rapidly. 
●  Treatments and diagnostics can be aligned with 
patient population and availability.  
●  Functional  use  of  systems  fit  with  clinician 
thought flow. 
●  Systems work together as a whole to facilitate, 
and not impede, clinician workflow. 
When evaluating oncology software on the market, 
it  is  equally  as  important  to  understand  a  vendor’s 
strategy  and  costs  for  licensing,  customisation  and 
enhancements, training and implementation, warranties, 
and  support  policies,  as  well  as  to  understand  the 
associated hardware and network requirements and the 
vendor’s  methods  for  quality  assurance.  Combining  a 
full evaluation of implementation and support costs and 
policies with an analysis of how well the system meets 
the  business  goals  and  the  needs  of  stakeholders  will 
contribute  to  a  successful  informatics  strategy. 
Communicating and promoting this strategy to software 
vendors is one way that the oncology industry can enlist 
the informatics industry to help achieve its goals. 
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Table 1  Elements of an Oncology Informatics Strategy. 
Business Goals 
•  Patient Safety 
•  Economics –Tracking and Management of Costs and 
Revenue 
•  Metrics for Measuring Quality of Cancer Care, 
Outcomes, and Performance 
•  Evidence based Medicine 
 
System Requirements 
•  Adaptable for Future Technologies in Diagnostics 
and Treatment 
•  Configurable for Patient Population Factors  
•  Designed for System Usability and Interoperability 
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